SeaStar Medical (ICU): Can the Stock Reach the $8.00 Analyst Target?
Key Takeaways
- The $8.00 target is the most widely cited public price objective for ICU, originating from a single named analyst at Maxim Group, not a multi-analyst consensus.
- ICU's analyst coverage is thin; the one current, attributable target is $8.00, set on May 14, 2026.
- At a recent close near $4.69, reaching $8.00 implies a gain of roughly 70%, a very large move.
- Supporting factors include accelerating QUELIMMUNE adoption, high gross margins, and the adult NEUTRALIZE-AKI pivotal trial.
- Key risks include heavy share dilution, ongoing operating losses, a small cash balance, and reliance on a single commercial product.
How the $8.00 Target Came About
SeaStar Medical Holding Corporation (ICU) does not have the broad sell-side coverage common among larger healthcare firms, so there is no solid multi-analyst consensus to reference. The $8.00 figure comes from the single active, named analyst target: Maxim Group's Anthony Vendetti raised his objective to $8.00 from $6.00 on May 14, 2026, keeping a Buy rating after first-quarter revenue, gross margin, and loss per share beat his estimates. Earlier in 2026, the same target had been trimmed to $6.00 from $10.00 to account for share dilution. Because this is one firm's view rather than a street-wide forecast, it reflects their assessment of the commercial rollout and pipeline.
Where ICU Stands Today and the Path Forward
The stock most recently closed near $4.69 on October 2, 2026, with after-hours and pre-market activity around $4.90 to $4.95 in early October 2026. The 52-week range runs from roughly $2.07 to $7.35. Moving from about $4.69 to $8.00 would require an increase of approximately 70%, a substantial shift for any security and especially challenging for a micro-cap with a market value near $20 million. Progress would hinge on sustained commercial execution in the pediatric market, advancement in the NEUTRALIZE-AKI adult trial, and the ability to fund operations without excessive dilution. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Factors That Could Support a Move Higher
Revenue is expanding rapidly from a small base: full-year 2025 revenue reached about $1.23 million, up from roughly $135,000 in 2024, and trailing twelve-month revenue stands near $1.71 million. Gross margin has been reported above 95%, reflecting a high-value device business. In the first quarter of 2026, the company added seven new QUELIMMUNE customers among top-tier children's hospitals, bringing its total to 17, and management has guided toward roughly $2 million in net product revenue for 2026. The adult opportunity is considerably larger, and the NEUTRALIZE-AKI pivotal trial had enrolled 198 of 339 patients as of mid-2026, with full enrollment targeted by the end of 2026. The SCD has also received FDA Breakthrough Device Designation for six indications, which could support faster development and future commercialization.
Risks That Could Hold the Stock Back
The company is not yet profitable, reporting a trailing twelve-month net loss of roughly $13.6 million, with total cash near $7 million. Continued cash burn may require further equity raises, and dilution remains a material concern: shares outstanding have increased more than fourfold in a year, which is precisely the factor Maxim cited when it previously cut its target. ICU remains a single-product story, with revenue concentrated in QUELIMMUNE, and adult commercialization depends on successful trial results and regulatory clearance that are not guaranteed. As a micro-cap with a negative beta and elevated volatility, the shares can swing sharply on limited news flow, and an RSI reading near 77 after a rapid rally suggests the stock may be stretched in the short term.
Technical Levels Worth Watching
The 52-week high near $7.35 stands as the most important nearby resistance zone, and it sits below the $8.00 objective. A sustained advance toward the target would first need to clear that prior high and then break into territory the stock has not traded in for over a year. On the downside, the 50-day and 200-day moving averages, both near $3.30, form a key support band that has underpinned the recent recovery from the 52-week low near $2.07. The stock's steep single-day gain of about 25% in early October reflects the kind of low-liquidity, sentiment-driven moves that can reverse quickly.
Time Horizon and Key Items to Monitor
A single analyst target of this kind is generally framed around a roughly twelve-month outlook, though the exact horizon is not disclosed in public summaries. Investors should watch the next quarterly report, estimated for November 12, 2026, for updates on QUELIMMUNE customer additions and revenue, the pace of NEUTRALIZE-AKI enrollment, and any commentary on cash runway and potential financing. Reimbursement developments, including the newly available ICD-10-PCS billing codes for SCD therapy, and any FDA milestones for the adult indication will also be relevant to whether the valuation case behind $8.00 strengthens or weakens. From what I see, tracking these elements closely will help clarify the setup.
AI Daily Buy/Sell Signals
In my research process, I often review Tickeron's AI Daily Buy/Sell Signals for an extra data-driven perspective on names like this. The system applies artificial intelligence to scan market conditions, technical behavior, and patterns across thousands of stocks and ETFs, producing Buy, Sell, or Hold signals that can help highlight potential shifts. It serves as a useful screening and monitoring layer alongside independent analysis rather than a replacement for it.
Final Assessment
The $8.00 objective for SeaStar Medical is best understood as a single named analyst's price target rather than a broad consensus, and it implies a gain of roughly 70% from recent levels near $4.69. The case for reaching it rests on rapid revenue growth, high-margin device economics, expanding pediatric adoption, and the larger adult pipeline opportunity. The case against it centers on persistent losses, a limited cash position, heavy dilution, and execution risk in both the commercial launch and the pivotal adult trial. With the 52-week high near $7.35 acting as a meaningful hurdle just below the target, investors should focus on quarterly results, trial enrollment, and financing decisions before drawing conclusions. No outcome is guaranteed, and the target represents a research viewpoint, not a forecast of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ICU in +15.54% Uptrend, advancing for three consecutive days on September 30, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ICU advanced for three days, in 145 of 180 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ICU just turned positive on September 09, 2026. Looking at past instances where ICU's MACD turned positive, the stock continued to rise in 26 of 45 cases over the following month. The odds of a continued upward trend are 58%.
ICU moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ICU crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 70 of 147 cases where ICU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 48%.
Bearish Trend Analysis
The 10-day RSI Indicator for ICU moved out of overbought territory on October 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 20 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 44 cases where ICU's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ICU as a result. In 77 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ICU broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.488) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (6.468) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. ICU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement